How are energy investors positioned?
In a recent transaction, Thomas L. Rodgers, Executive Vice President, Chief Strategy & BDO of McKesson Corp (NYSE:MCK), sold 510 shares of the company’s common stock. The shares were sold at a price of $717.91 each, resulting in a total transaction value of $366,134. Following this sale, Rodgers holds 5,435 shares of McKesson, which is currently trading near its 52-week high of $731 and has delivered strong returns over the past five years. This transaction was executed under a previously adopted plan compliant with Rule 10b5-1(c), dated August 17, 2024. For comprehensive insider trading analysis and 14 additional key insights about McKesson, visit InvestingPro.
In other recent news, McKesson Corporation reported strong financial performance for its fiscal fourth quarter and full year 2025, with earnings per share (EPS) exceeding expectations. The company achieved a 20% year-over-year growth in EPS and consolidated revenues increased by 16% to $359.1 billion. Despite these positive results, McKesson’s revenue for Q3 2025 fell short of forecasts, coming in at $90.82 billion against an expected $93.48 billion. Jefferies analyst Rob Dickerson raised McKesson’s stock target to $800, maintaining a Buy rating, citing the company’s appealing valuation and positive earnings report. McKesson has also projected revenue growth of 11% to 15% for fiscal 2026, with an anticipated EPS range of $36.05 to $37.55. The company plans to separate its Medical (TASE:BLWV) Surgical segment into an independent entity to enhance operational focus. Strategic acquisitions, such as controlling interests in Prism Vision and pending acquisitions in CORE Ventures, continue to bolster McKesson’s growth in the healthcare services sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.